News Square
Global Crypto News · Real-time Aggregation
📚 Deep Analysis
More →GRVT Burns 1.1 Million Tokens as Countdown to Grvt 2.0 Begins
<strong>[PRESS RELEASE – Singapore, Singapore, October 20th, 2026]</strong> <strong>The discretionary buyback represents close to 1% of circulating supply and precedes four planned product milestones culminating in Grvt 2.0.</strong> <a href="https://grvt.io/" rel="nofollow noopener" target="_blank">>Grvt</a>, a self-custodial trading platform built on its own zero-knowledge (ZK) chain, announced that the Foundation’s token issuer has completed its first GRVT token buyback, purchasing and burning 1.1 million GRVT tokens on the open market. The transaction permanently removed close to 1% of GRVT’s circulating supply at the time of purchase. It marks the first of five milestones ahead of the planned launch of Grvt 2.0 at the end of November 2026. <strong>A Discretionary Buyback with On-Chain Verification</strong> The Foundation’s token issuer intends to conduct further buybacks on a monthly basis. Each transaction remains entirely at the issuer’s discretion, with no predetermined purchase amount or guaranteed schedule. Buybacks are executed through an independent execution partner, with purchased tokens transferred to a designated burn address and permanently removed from circulation. The transactions can be independently verified through the <a href="https://grvt.io/exchange/buybacks" rel="nofollow noopener" target="_blank">>public buyback dashboard</a>, which records the number of tokens purchased and burned, the percentage of circulating supply represented, cumulative burns and on-chain transaction hashes. “The GRVT token is an important part of the ecosystem we are building,” said <strong>Hong, co-founder and CEO of Grvt</strong>. “We welcome the issuer’s buybacks as a demonstration of its long-term commitment to the ecosystem and community. Grvt is expanding its products and markets, and the issuer’s buybacks sit alongside that as a supportive mechanism aimed at reducing circulating token supply.” <strong>Grvt Outlines Four Product Milestones</strong> The announcement follows GRVT’s token generation event in July 2026 and precedes a series of planned launches. <strong>Grvt Earn, scheduled for the End of October,</strong> will introduce yield opportunities backed by tokenized assets, with target yields of up to 11%. Potential returns are expected to derive from underlying asset cash flows, including interest, premiums and invoice-related income. Asset-supplying partners will be announced at launch. Target yields are not guaranteed. <strong>Stable Funding Perps, scheduled for November,</strong> will introduce perpetual futures linked to commodities, stocks, foreign exchange and indices. The contracts are planned to carry zero trading fees and use once-daily funding. Grvt aims to list more than 1,000 markets by the end of December 2026. <strong>Yield as Margin, also scheduled for November,</strong> will allow eligible Grvt Earn balances to support trading positions while continuing to accrue yield, subject to applicable product terms
OpenAI Buys Orchestra Bio to Put AI Agents in Charge of Drug Development Grunt Work
OpenAI has bought Orchestra Bio, a San Francisco startup whose AI agents help drug companies keep sprawling development programs on schedule, the ChatGPT maker <a href="https://openai.com/index/openai-to-acquire-orchestra-bio/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>announced Tuesday</a>. “Our goal is to help scientists make discoveries and manage the work needed to turn them into treatments that reach patients sooner,” OpenAI said in the announcement. Orchestra’s team and platform will be folded into <a href="https://openai.com/rosalind/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>Rosalind</a>, OpenAI’s family of AI models and tools for biologists and chemists. The financial terms were not disclosed. Getting a new medicine from first idea to U.S. approval takes time—up to 15 years according to OpenAI. Every month shaved off that timeline is a month earlier that a new treatment can reach the people waiting for it, and a month earlier that the company can generate cash. The process is also absurdly expensive: bringing one approved drug to market can cost more than <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12668846/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>$2.6 billion</a>, and <a href="https://arxiv.org/pdf/2106.05386" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">fewer than 10%</a> of candidates that enter human testing ever make it to pharmacy shelves. Beyond the science itself, OpenAI says drug teams have to coordinate work across internal departments and outside partners, often relying on systems that don’t talk to each other. Those partners usually include contract research organizations, the outside labs hired to run studies, and contract manufacturers that produce the experimental drug. Orchestra’s AI agents—software that can watch over tasks and flag problems on its own—work out which activities and deadlines take the hit, gather the relevant information and compare ways to respond, while scientists and program leaders make the final call. Founded in the fall of 2022, Orchestra raised its <a href="https://jobs.8vc.com/companies/orchestra/jobs/28818089-senior-software-engineer" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>seed round</a> from Andreessen Horowitz, Definition Capital, Insight Partners, and 8VC, and about $20 million in total, according to <a href="https://www.caplight.com/company/orchestra-bio" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">Caplight data</a>. The company should not be confused with Orchestra BioMed, an unrelated Nasdaq-listed medical device maker that trades under the ticker OBIO. In April, OpenAI launched <a href="https://decrypt.co/364783/openai-gpt-rosalind-drug-discovery-life-sciences-model" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">GPT-Rosalind</a>, a model built specifically for biology and dru
The SEC will continue to accept public comments on the crypto regulatory proposal.
CoinWorld news, according to Cointelegraph, the U.S. Securities and Exchange Commission (SEC) will continue to accept public comments on its crypto regulatory proposal even after today's deadline.
Ripple submits comment letter supporting SEC's crypto asset rule proposal
CoinWorld news, Ripple Chief Legal Officer Stuart Alderoty stated that Ripple has submitted a comment letter to the U.S. SEC in support of its proposed crypto asset regulatory rules, and believes that the U.S. SEC has clear authority to adopt such rules. He pointed out that the industry needs holistic rules for digital assets, and that the proposal is faithful to the Howey Test—what constitutes a security is the investment contract, not the token itself. Ripple has spent more than $150 million to clarify the relevant rules.
Bitcoin在Coinbase的交易价格低于Binance和OKX 115美元
Data from Bijie: Bitcoin is trading $115 lower on Coinbase compared to Binance and OKX. Against the backdrop of ETFs buying over $500 million yesterday, heavy selling pressure has emerged in the U.S. spot market.
The U.S. special envoy will present a new version of the Ukraine peace plan to Putin.
According to AXIOS, U.S. officials said that White House envoy Witkoff will meet with Russian President Putin in St. Petersburg, Russia, on Wednesday and present him with an updated plan to end the war in Ukraine. The White House hopes that Putin will show greater willingness to compromise after Trump agreed to lift sanctions on Russian diesel sales and take other measures welcomed by Moscow. Before traveling to Russia, Witkoff held a day of talks with Ukrainian President Zelensky in Oslo, Norway, and consulted with the leaders of Norway and Finland as well as representatives from France, the United Kingdom, Germany, Poland, the European Union, and NATO. A U.S. official said that the United States hopes the new plan can "create a viable path for direct trilateral negotiations as well as broader multilateral negotiations."
The US-Iran compromise plan stirs the market, and crude oil stages a V-shaped move.
CoinWorld news: The US-Iran compromise plan roils the market, crude oil prices stage a V-shaped move, and the Dow Jones index rises 1%. Qatar and Pakistan submit a compromise proposal to the US and Iran, and oil prices fall more than 3% at one point during the session. The spread between French and German 10-year government bonds widens past 150 basis points; US Treasury Secretary Bessent says it is not expected to spill over, and safe-haven funds are flowing into US Treasuries. China's central bank keeps its October LPR quotes unchanged for the 17th consecutive month, with the 1-year rate at 3.0% and the 5-year-and-above rate at 3.5%. The National Development and Reform Commission says it will introduce incremental policies and study an implementation plan for the strategy of expanding domestic demand. Zhou Xiaochuan says financial risks from failed AI investments should be addressed. SpaceX's third-quarter revenue reaches $14.58 billion, up 161% year on year, AI business revenue surges 830%, and net profit exceeds expectations by 2.3 times. Netflix's fourth-quarter revenue guidance and advertising revenue both fall short of expectations, and its shares drop more than 5% after hours. Super Micro Computer's first-quarter results show revenue growth of 27%, and its shares soar 11% after hours.
Tesla's Optimus continues to advance toward mass production, and OpenAI confirms it is developing its own humanoid robot.
CoinWorld news: Tesla's Optimus project continues to advance toward mass production, and OpenAI has confirmed that it is developing its own humanoid robot. Meanwhile, the company's high-precision positioning products are also serving the humanoid robotics and intelligent driving sectors, playing a core role.
BTC/ETH/SOL 12-hour liquidation pain point update
CoinWorld data: BTC is currently priced at 82,998 USDT, with the downside long pain point at 80,748 (-2.71% from the current price, estimated strength 140 million USDT), and the upside short pain point at 83,672 (+0.81% from the current price, estimated strength 87.2657 million USDT); ETH is currently priced at 2,452 USDT, with the downside long pain point at 2,363.4 (-3.61% from the current price, estimated strength 56.9058 million USDT), and the upside short pain point at 2,485.6 (+1.37% from the current price, estimated strength 46.998 million USDT); SOL is currently priced at 106.6 USDT, with the downside long pain point at 104.9 (-1.59% from the current price, estimated strength 17.2775 million USDT), and the upside short pain point at 108.7 (+1.97% from the current price, estimated strength 12.3405 million USDT).
Fireworks AI is seeking funding at a valuation of up to $40 billion.
CoinWorld news, Fireworks AI is seeking a new round of financing with a target valuation of $30 billion to $40 billion. According to Business Insider citing people familiar with the matter, the company's valuation was $17.5 billion a few months ago. The financing negotiations are still in the early stages, and the target valuation may change. Unlike companies trying to build a ChatGPT competitor, Fireworks AI has chosen to serve enterprises by customizing AI models using customers' proprietary data and specific business needs. In July of this year, the company said its annualized revenue had exceeded $1 billion, processing more than 40 trillion tokens per day, 95% of which came from models customized to customer needs.